SENECA THERAPEUTICS
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics and derivatives as cancer therapeutics, cancer vaccines, and vaccines for the treatment of cancer. This oncolytic immunotherapeutic is called Seneca Valley Virus (SVV) which eliminates tumor cells in which it can replicate. Seneca Therapeutics is headquartered in Blue Bell, Pennsylvania.
SENECA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Blue Bell, Pennsylvania, United States
Country:
United States
Website Url:
http://www.senecatherapeutics.com
Status:
Active
Contact:
484-883-9725
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Organization Schema Microsoft Azure DNS
Similar Organizations
Biopep Solutions
Biopep Solutions is a biotechnology company that discovers and develops therapeutic products for the treatment of cancer and other diseases.
Netnoids Rx Laboratories
Netnoids Rx Laboratories uses patient-derived organoid model systems to help find a cure for rare cancers.
SciSafe
SciSafe is a biotechnology company that offers dedicated pharmaceutical and biological specimen storage in its state of the art facility.
Current Employees Featured
Founder
Investors List
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels investment in Venture Round - Seneca Therapeutics
Broad Street Angels
Broad Street Angels investment in Venture Round - Seneca Therapeutics
Official Site Inspections
http://www.senecatherapeutics.com Semrush global rank: 6.57 M Semrush visits lastest month: 954
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Seneca Therapeutics"
Our Team - Seneca Therapeutics Therapeutics
Mark Kerschner - chief financial officer. Mr. Kerschner is the Chief Financial Officer of Seneca Therapeutics. He began his career with PWC in New York City and has held various corporate …See details»
Seneca Therapeutics - Crunchbase Company Profile & Funding
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.See details»
Our Mission — Seneca Therapeutics Therapeutics
Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001).See details»
Seneca Therapeutics, Inc. | LinkedIn
Seneca Therapeutics, Inc. Biotechnology Research Philadelphia, PA 450 followers Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients with solid cancersSee details»
Seneca Therapeutics - PitchBook
Seneca Therapeutics General Information Description. Developer of complex targeted biologics intended to offer therapeutics and vaccines for solid cancer. The company focuses on …See details»
Seneca Therapeutics - Overview, News & Similar companies
Nov 27, 2023 Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at Oncolytic Virotherapy Summit 2023 on December 13 PHILADELPHIA--(BUSINESS WIRE)- …See details»
Seneca Therapeutics Receives FDA Clearance to Begin …
Oct 3, 2022 Paul Hallenbeck CSO and President [email protected]. James Hussey CEO [email protected]. www.senecatherapeutics.com. Contacts.See details»
SVV-044 - Drug Targets, Indications, Patents - Synapse - Patsnap
Originator Organization. Seneca Therapeutics, Inc. Startup. Active Organization. Seneca Therapeutics, Inc. Startup. Inactive Organization-Drug ... Contacts Paul Hallenbeck …See details»
Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to ...
PHILADELPHIA, November 27, 2023--Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled "Facilitating multiple deliveries of therapeutic viruses by …See details»
Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to ...
Nov 27, 2023 www.senecatherapeutics.com. Contacts. Paul Hallenbeck CSO and President [email protected]. James Hussey CEO …See details»
Seneca Therapeutics, Inc. Receives Positive Feedback from FDA on ...
Sep 14, 2020 PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immunotherapeutics for …See details»
Latest News — Seneca Therapeutics Therapeutics
Nov 15, 2023 www.senecatherapeutics.com. Mason Duling. October 30, 2023. Seneca Therapeutics Garners Prestigious Recognition at Keiretsu Forum’s Investor Capital Expo. …See details»
Seneca Therapeutics, Inc. Announces Launch of a Novel Cancer …
Sep 21, 2021 PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic …See details»
Our Science — Seneca Therapeutics Therapeutics
Seneca Valley Virus Seneca’s lead asset is SVV-001 (SVV), an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to selectively …See details»
Seneca Therapeutics Expands Product Pipeline Adding Six New …
Feb 8, 2021 PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic …See details»
Seneca Therapeutics Announces Publication of AACR Abstract ...
Mar 9, 2022 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca VaSee details»
Pipeline — Seneca Therapeutics Therapeutics
Seneca Therapeutics currently has an open IND for a Clinical Trial titled “ A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab in Patients with Poorly Differentiated …See details»
Seneca Therapeutics, Inc. Announces Issued U.S Patents for Tumor ...
Aug 24, 2021 Seneca Therapeutics, Inc. Announces Issued U.S Patents for Tumor Endothelial Marker 8 (TEM8) Technology to Enable Better Patient Selection for SVV-001 TherapySee details»
Seneca Therapeutics, Inc. to Present at the World ... - Business Wire
Apr 18, 2022 Seneca Therapeutics, Inc. to Present at the World Vaccine Congress in Washington, DC April 18-21, 2022See details»